11/22/2017

New Gout Drug Krystexxa Exceeds Target

New Gout Drug Krystexxa Exceeds Target

There is increased hope for the roughly 3% of chronic, severe gout sufferers who do not respond to current gout medications. Within recent period III trials of the new gout medication Krystexxa, a great impressive 42% of refractory gout patients achieved statistically significant reductions in uric acid levels, as well as sustained all of them for six months. This exceeeded the target amount set for the study by the drug's manufacturer, Savient Pharmaceuticals. In comparison, these gout patients in the trial that received a placebo saw no reduction in uric acid levels.

When you have seriously ill people who have no options, 40 percent will be pretty good," said Dr. Michael Becker from the University of Chicago," author of the most recent study, which was published in the Journal of the American Medical Association. "Gout can be a sincere about and disabling disease."

Krystexxa (generic name plegloticase) has been FDA approved in 2010 based on earlier clinical trials. The new gout treatment, which is administered by intravenous infusion, is derived from an animal hormone. The pegloticase mechanism of action is different than that of other gout drugs - it converts uric acid to a nontoxic byproduct that is easily excreted in the urine.

  • High levels of uric acid are usually the cause of gout, an extremely painful form of arthritis.
  • The excess acid crystallizes into filling device sharp debris in the joints, usually at the bottom of the big toe.
  • The particular uric acid can also form knobby, chalky mounds called tophi.
  • Tophi can be reabsorbed back into the body if uric acid levels are reduced.
  • Forty percent of the trial participants with tophi knowledgeable a resolution of one or more of the lumpy deposits.

Goutezol High Uric Acid Relief

Goutezol High Uric Acid Relief

Goutezol Gout Relief contains botanical ingredients created to gently support healthy uric acid metabolism. Goutezol's active ingredients have been used safely for many years to support healthy uric acid metabolism, help reducing high uric acid levels. Now they are all integrated into this unique gout formula. Decreasing uric acid and supporting uric acid metabolism has been shown to eliminate the flare-ups associated with gout.
More about This Product »

Krystexxa Emerged Intravenously Over At Least Two Hours Every Two Weeks

The Food and drug administration has warned that patients should be given a corticosteroid and antihistamine before infusions because of a high risk of allergic reaction. Other common side effects of Krystexxa are gout flare ups (which occurred in 80% of the recent trial participants), nausea and vomiting, chest pain, constipation, nasal irritation and bruising at the injection site.

Gout,Uric Acid,Uric,Gout Patients,Uric Acid Levels,Gout Drug,Allopurinol Gout,Severe Gout,Gout Information,Gouty Arthritis,Gout Flare,Gout Gout,Gout Flare Ups

Krystexxa is not intended for use in the common gouty arthritis patient, most of which can be treated with more traditional gout medications such as Colcrys (generic colchicine) or Zyloprim (generic allopurinal). Currently, the new injectable gout drug costs about $5000 a month. It's hoped that gout patients who respond well to the treatment could eventually use cheaper gout drugs.

Armed with these extraordinary new results, Savient Pharmaceuticals promises to amp up promotion of its new gout drug in the US and other countries. Up to now, their advertising efforts have largely been aimed at rheumatologists, but they now plan to expand their particular efforts to include primary care physicians. "This really now is the foundation for our launch of phase 2 into the primary care audience," said Savient Chief Executive Officer John Johnson.

How to Cure Gout in 24 hours Naturally

http://draxe.com/ In this video, I'm going to share with you my top 6 home remedies for gout. Gout is caused by uric acid build up in the body. First I want to go ...

Johnson says the pharmaceutical company "expects to see several velocity inside sales" as a result of their increased target market. The organization is said to be disappointed in the $1.4 thousand dollars in net sales the gout medication generated in the first six months after receiving Food and drug administration approval.

Alex Ray Advocates for Affordable Access to Healthcare and Medication

She recommends Big Mountain Drugs as a reliable on the internet Canadian pharmacy from which to buy colchicine as well as allopurinol for gout. For more information about gout and gout medication, visit the online resource www.colchicine.ca.

Domenic GoldenDomenic Golden
Domenic is a head content marketing specialist at musclenstress.com, a collection of articles on health issues. In the past, Domenic worked as a post curator for a well-known health site. When he's not writing posts, Domenic enjoys drawing and rock climbing.